Dangerous Drugs Act

Section 28A: Interpretation of Part IIA

PART IIA: MEDICINAL CANNABIS

Dangerous Drugs ActSection 28A

28A. Interpretation of Part IIA In this Part – “authorised patient” means a patient who is, pursuant to section 28F, issued with a prescription to be treated with medicinal cannabis; “authorised pharmacist” means a Government pharmacist who – (a) has successfully completed a training course, as approved by the Ministry, on the therapeutic use of medicinal cannabis; and (b) is authorised, in writing, by the Ministry to handle and dispense medicinal cannabis; “authorised specialist” means a specialist who – (a) is registered as such under section 20 of the Medical Council Act; Acts 2022 535 (b) has successfully completed a training course, as approved by the Ministry, on the therapeutic use of medicinal cannabis; and (c) is authorised, in writing, by the Ministry to make a request for, and to issue a prescription to, a patient to be treated with medicinal cannabis; “specific therapeutic conditions” – (a) means – (i) spasticity, associated with multiple sclerosis, that has failed to respond to conventional treatment; (ii) severe refractory epilepsy that has failed to respond to conventional anti-convulsant treatment; (iii) intractable nausea and vomiting, associated with chemotherapy, that has failed to respond to conventional anti-emetic treatment; or (iv) severe intractable pain that has failed to respond to conventional treatment; and (b) includes such other therapeutic conditions as may be authorised by the Medicinal Cannabis Therapeutic Committee based on therapeutic evidence.

This section is inserted by Dangerous Drugs (Amendment) Act 2022, section 7.

Start date not held: comes into operation on a date fixed by Proclamation, and juris holds no Proclamation for it.

consolidated text (as at 2013, amended since). juris shows the text as it was consolidated; it does not confirm that this is the law in force today.

Ask juris about this section Official source